论文部分内容阅读
研究对象为临床诊断的慢性丙型肝炎患者40例,其中男性33例,女性7例;年龄18～61岁,平均44岁。给予重组干扰素α2a(r-IFNα2a)6×10~6IU/日,连续用药3周后,改为3×10~6IU/日,每周3次,间歇用药6个月,对 IFN 无效病例,可接着按上述时间间歇用药,并从 HCV 相关标记、肝功能及副作用等方面进行探讨。结果:在 HCV 相关抗体中 C100-3抗体阳性者82.5%;在核心抗体中,CP9抗体阳性者82.5%,而CP10抗体阳性者95.0%;有任一种抗体阳性者38例(95.0%)。应用 IFN 治疗后 C100-3抗体阳性为7例(21.2%),核心抗体1例(3%)转阴,全部病例的
Forty patients with clinically diagnosed chronic hepatitis C were studied, including 33 males and 7 females, aged 18-61 years, mean 44 years old. The recombinant interferon α2a (r-IFNα2a) 6 × 10 ~ 6IU / day, continuous medication for 3 weeks, to 3 × 10 ~ 6IU / day, three times a week, intermittent medication for 6 months, IFN ineffective cases, This can be followed by intermittent dosing as described above, and from HCV-related markers, liver function and side effects. Results: The positive rate of C100-3 antibody in HCV-related antibody was 82.5%. Among the core antibody, CP9 antibody positive was 82.5% and CP10 antibody positive was 95.0%. There were 38 cases (95.0%) positive in any antibody. After treatment with IFN, C100-3 antibody was positive in 7 cases (21.2%) and core antibody in 1 case (3%) was negative. All patients